Carl Zeiss Meditec AG
XMUN:AFX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Carl Zeiss Meditec AG
XMUN:AFX
|
DE |
|
D
|
Diamyd Medical AB
F:DMN
|
SE |
Carl Zeiss Meditec AG
Carl Zeiss Meditec makes medical equipment used mainly in eye care and microsurgery. Its products include devices for diagnosing eye diseases, lasers and surgical systems for eye operations, and microscopes and imaging tools used in the operating room. In simple terms, it sells the hardware doctors and hospitals use to examine eyes, plan treatment, and perform procedures. Its main customers are eye clinics, hospitals, ophthalmologists, and other medical specialists. The company earns money by selling equipment and related software, along with service contracts, maintenance, and consumables that support the installed base of machines. That gives it a mix of upfront equipment sales and more recurring follow-on revenue. What makes the business distinctive is its position in precision eye care. It sits between advanced optics and medical technology, so its products need to be highly accurate, reliable, and trusted by surgeons. The company benefits from the long replacement cycles and technical complexity of medical devices, where customers value performance, training, and ongoing service.
Carl Zeiss Meditec makes medical equipment used mainly in eye care and microsurgery. Its products include devices for diagnosing eye diseases, lasers and surgical systems for eye operations, and microscopes and imaging tools used in the operating room. In simple terms, it sells the hardware doctors and hospitals use to examine eyes, plan treatment, and perform procedures.
Its main customers are eye clinics, hospitals, ophthalmologists, and other medical specialists. The company earns money by selling equipment and related software, along with service contracts, maintenance, and consumables that support the installed base of machines. That gives it a mix of upfront equipment sales and more recurring follow-on revenue.
What makes the business distinctive is its position in precision eye care. It sits between advanced optics and medical technology, so its products need to be highly accurate, reliable, and trusted by surgeons. The company benefits from the long replacement cycles and technical complexity of medical devices, where customers value performance, training, and ongoing service.
Weak first half: Carl Zeiss Meditec said 6-month revenue and earnings were weak, hit by currency headwinds, an unfavorable product mix, and softer demand in key markets, especially China and the Americas.
Profitability fell: Adjusted EBITA dropped to EUR 60.5 million, with the margin down to 6.1% from 10.7% a year ago, mainly due to FX, mix, lower operating leverage, and a one-off R&D impairment.
ProfitUp launched: Management unveiled a broad restructuring and portfolio program, ProfitUp, targeting more than EUR 200 million in annual profit improvement by fiscal 2028/29, with about 1,000 positions potentially affected.
Full-year outlook: The company guided to EUR 2.15 billion to EUR 2.2 billion in revenue and an adjusted EBITA margin of 8% to 10% for fiscal 2025/26, calling the year a “tale of two half-years.”
China caution: Management expects China refractive to recover seasonally, but remains cautious on competition and pricing, especially ahead of the next NVBP round expected around June to July.
Midterm target: The company still sees organic revenue growth returning to at least mid-single digits over the medium term and adjusted EBITA margin above 15% by fiscal 2028/29.